Skip to main content
SpringerLink
Log in
Book cover

Myeloma Therapy pp 91–98Cite as

Maintenance Therapy in Multiple Myeloma

  • Chapter

Part of the book series: Contemporary Hematology ((CH))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Mihelic R, Kaufman JL, Lonial S. Maintenance therapy in multiple myeloma. Leukemia. 2007;21(6):1150–1157.

    Article  PubMed  CAS  Google Scholar 

  2. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003;98:1337–1354.

    Article  PubMed  Google Scholar 

  3. Berinstein NL. Principles of maintenance therapy. Leuk Res. 2006;30(Suppl. 1): S3–S10.

    Article  PubMed  CAS  Google Scholar 

  4. Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus statement. Mayo Clin Proc. 2007;82:323–341.

    Article  PubMed  CAS  Google Scholar 

  5. Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001;113:1020–1034.

    Article  Google Scholar 

  6. Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: Meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol. 2000;11:1427–1436.

    Article  PubMed  CAS  Google Scholar 

  7. Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002;99: 3163–3168.

    Article  PubMed  CAS  Google Scholar 

  8. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol. 2002;13:1116–1119.

    Article  PubMed  CAS  Google Scholar 

  9. Stewart AK, Chen CI, Howson-Jan K, et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res. 2004;10:8170–8176.

    Article  PubMed  CAS  Google Scholar 

  10. Feyler S, Graham J, Rawstron A, EL-Sherbiny Y, Snowden J, Johnson R. Thalidomide maintenance following high dose therapy in multiple myeloma: A UK Myeloma Forum Phase 2 Study. Blood. 2003;102:Abstract #2558.

    Google Scholar 

  11. Feyler S, Rawstron A, Jackson G, Snowden J, Hawkins K, Johnson RJ. Thalidomide maintenance following high dose therapy in multiple myeloma: a UK Myeloma Forum phase 2 study. ASH Annual Meeting Abstracts. Blood. 2003;106:641–691a.

    Google Scholar 

  12. Brinker BT, Waller EK, Leong T, Heffner LT, Redei I, Langston AA, Lonial S. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer. 2006;106:2171–2180.

    Article  PubMed  CAS  Google Scholar 

  13. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289–3294.

    Article  PubMed  CAS  Google Scholar 

  14. Spencer A, Prince M, Roberts AW, Bradstock KF, Prosser IW. First analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLG MM6). ASH Annual Meeting Abstracts. 2006;108:58–77a.

    Google Scholar 

  15. Spencer AP, Prince M, Roberts AW, Bradstock KF, Prosser IW. Thalidomide improves survival when used following ASCT. Haematologica. 2007;92:41–42.

    Article  Google Scholar 

  16. Peles S, Fisher NM, Devine SM, Tomasson MH, DiPersio JF, Vij R. Bortezomib (Velcade) when given pretransplant and once weekly as consolidation therapy following high dose chemotherapy (HDCT) leads to high rates of reactivation of Varicella Zoster Virus (VZV). ASH Annual Meeting Abstracts. 2005;106:3237–905a.

    Google Scholar 

  17. Schiller GJ, Sohn JP, Malone R, et al. Phase I/II Trial of Bortezomib maintenance following autologous peripheral blood progenitor cell transplantation as treatment for intermediate- and advanced-stage multiple myeloma. ASH Annual Meeting Abstracts. 2006;108:5433–453b.

    Google Scholar 

  18. Knop S, Hebart H, Kunzmann V, Angermund R, Einsele H. Bortezomib once weekly is well tolerated as maintenance therapy after less than a complete response to high-dose melphalan in patients with multiple myeloma. ASH Annual Meeting Abstracts. 2006;108:5099–364b.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA

    Jonathan L. Kaufman & Sagar Lonial

Authors
  1. Jonathan L. Kaufman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald Mihelic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sagar Lonial
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Winship Cancer Institute, Emory University, B3307 Clifton Road, Atlanta, GA, 30322, USA

    Sagar Lonial MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kaufman, J.L., Mihelic, R., Lonial, S. (2008). Maintenance Therapy in Multiple Myeloma. In: Lonial, S. (eds) Myeloma Therapy. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-564-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-564-0_7

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-82-4

  • Online ISBN: 978-1-59745-564-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation